Amelia Insa Molla

9PUBLICATIONS
84CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 10, 2026
Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Belén Sierra-Rodero, Ángeles Gil-González, Marta Molina-Alejandre

|Jan 15, 2026
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.

Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal

|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

Tina Cascone, Laura Bonanno, Florian Guisier

|Mar 08, 2023
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.

Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Javier De Castro

|Feb 22, 2023
Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.

Javier De Castro, Amelia Insa, Roberto Collado-Borrell

|Sep 28, 2022
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Marta Casarrubios, Mariano Provencio, Ernest Nadal

Pageof 2

Frequent Collaborators

6 joint publications

Alberto Cruz-Bermúdez

6 joint publications

Ernest Nadal

6 joint publications

Mariano Provencio Pulla

6 joint publications

Alex Martínez-Martí